| 2026-08-14 | Press release | 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results |
| 2026-07-30 | Press release | 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules |
| 2026-07-19 | Presentation | Investor Presentation |
| 2026-07-08 | Press release | 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine |
| 2026-07-01 | Press release | 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study |
| 2026-06-11 | Press release | 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription U |
| 2026-05-26 | Press release | 60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Pat |
| 2026-05-15 | Press release | 60 Degrees Pharmaceuticals Announces First Quarter 2026 Results |
| 2026-04-15 | Press release | 60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Websit |
| 2026-03-31 | Press release | 60 Degrees Pharmaceuticals Announces 2025 Annual Results |
| 2026-03-18 | Press release | 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract |
| 2026-03-11 | Press release | PDF Version |
| 2026-02-02 | Press release | PDF Version |
| 2026-01-28 | Press release | PDF Version |
| 2026-01-22 | Press release | PDF Version |
| Press release | Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafen |
| Press release | 60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital |
| Press release | 60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch |
| Press release | 60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rul |
| Press release | 60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules |
| Press release | 60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements |
| Press release | 60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb |
| Press release | 60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split |
| Press release | 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support |
| Press release | 60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study |
| Press release | 60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromis |
| Press release | First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Cente |
| Press release | 60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Bab |
| Press release | Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; |
| Press release | 60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinar |
| Press release | 60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infecti |
| Press release | 60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes |
| Press release | 60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis |
| Press release | 60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris |
| Press release | 60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering |
| Press release | 60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering |
| Press release | 60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting |
| Press release | 60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements |
| Press release | 60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Ti |
| Press release | 60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment a |